TR128 in Patients With Advanced Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2025-05-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a open-label, 3+3 design, dose escalation and expansion, phase I study, to evaluate the safety and tolerability, and to determine the RP2D of TR128 when administered qd in patients with advanced solid tumors. Up to 5 cohorts of 3-6 patients each will be treated in dose escalation phase of the study. One cycle is 28 days. Dose expansion phase to further evaluate the safety, tolerability and preliminary anti-tumor activity of TR128 at the RP2D.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tarapeutics Science Inc.

Criteria

Inclusion Criteria:

• fully understand the procedures of the clinical study and participate voluntarily with signed and dated written informed consent form, comply with the requirements of the study protocol.

• males and/or females at least 18 years old when signing the informed consent form.

• histologically or cytologically confirmed patients with advanced malignant solid tumors, eligible patients must have failed standard treatment, no standard treatment, or not suitable for standard treatment at this stage as determined by the investigator.

• measurable disease with at least one leasion amenable to response assessment per RECIST 1.1.

• eastern cooperative oncology group performance status (ECOG) ≤1 at screening.

• life expectancy of at least 3 months.

• acceptable organ function: Absolute neutrophil count(ANC)≥1.5×109/L; Platelet count(PLT)≥90×109/L; Hemoglobin(Hb)≥90 g/L; INR or PT≤1.5×Upper limit of normal value (ULN), APTT≤1.5×ULN ; Total bilirubin(TBIL)≤1.5×Upper limit of normal value(ULN) (≤3× ULN if there is liver involvement); Alanine aminotransferase(ALT)≤2.5×ULN and aspartate aminotransferase(AST)≤2.5×ULN (≤ 5 × ULN if there is liver involvement); Cr ≤1.5×ULN or CCr ≥50 ml/min (calculated by Cockcroft-Gault formula).

• fertile male and female must agree to use medically approved contraceptives during the study and within 6 months after the last dose of the study.

Exclusion Criteria:

• medical history and surgical history excluded according to the protocol.

• any previous medical treatment history exclude from the protocol.

• abnormal laboratory results exclude from the protocol.

• pregnant and lactating women (currently breast-feeding or less than six months after delivery although not breast-feeding).

• unsuitable for the study by the investigator's judgment.